Company Overview
NeuroOne Medical Technologies Corporation operates within the healthcare sector, specifically focusing on the medical devices industry where it provides specialized recording solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) in the United States. The company's product portfolio also extends to include solutions for spinal cord stimulation, brain stimulation, and drug delivery systems. In terms of scale, NeuroOne Medical Technologies Corporation carries a market capitalization of $37.21M and reports an annual revenue of $11.72M based on trailing twelve-month figures. The organization employs a workforce of 18 individuals to support its operations. These valuation and revenue metrics indicate that the company functions as a small-cap entity with a relatively modest revenue base compared to large-cap medical device peers, suggesting a niche operational scope focused on specific neurological monitoring and stimulation technologies rather than broad-market hardware manufacturing.
Financial Health
The company reported a revenue of $11.72M for the trailing twelve months, yet this generated a net income of -$6,828,586, revealing a significant gap that indicates a highly cost-heavy structure where operating expenses far outpace gross profits. This disparity is further highlighted by an EBITDA of -$7,382,912, which underscores the substantial cash burn occurring before interest and tax adjustments. The company's financial flexibility is currently constrained by a free cash flow of -$3,917,580, indicating an inability to generate internal cash reserves to fund operations or capital expenditures without external financing. Margin analysis reveals a gross margin of 22.0%, which suggests that the cost of goods sold consumes a large portion of revenue before overhead is considered. However, the operating margin stands at -59.0% and the profit margin is -58.3%, both of which indicate that high fixed costs or inefficient operational scaling are severely eroding profitability at every level of the income statement. Regarding liquidity and leverage, the company holds $3.56M in cash against a debt obligation of $237,377, resulting in a debt-to-equity ratio of 3.71. While the debt load is low in absolute terms, the high debt-to-equity ratio suggests a leveraged balance sheet relative to shareholders' equity, though the substantial cash balance provides a significant buffer against immediate solvency risks. The current ratio is 6.41, which indicates a very strong short-term liquidity position where current assets significantly exceed current liabilities. Furthermore, the return on equity is -146.3% and the return on assets is -63.4%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and the total asset base, respectively.
Valuation Assessment
The valuation profile of NeuroOne Medical Technologies Corporation is complex due to its lack of profitability, evidenced by a trailing P/E ratio that is N/A and a forward P/E of -2.62. The negative forward P/E implies that the market is pricing the stock based on expectations of future earnings normalization rather than current performance, suggesting a speculative valuation framework. The price-to-book ratio is 5.78, which indicates that the market is trading the company at a significant premium over its tangible book value, a scenario often seen in growth-oriented biotech or medical device firms despite current losses. Alternative valuation metrics provide further context, with a price-to-sales ratio of 3.18 and an EV/EBITDA of -4.57, suggesting that investors are valuing the firm primarily on its revenue generation potential rather than its earnings power. In terms of trading range, the stock has a 52-week high of $1.16 and a 52-week low of $0.40. Assuming a current price near the lower end of this historical range, the stock is trading significantly below its 52-week high, reflecting recent market pressure or lack of upward momentum. The beta value is 0.69, which means the stock exhibits lower volatility relative to the broader market, moving less dramatically than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year stands at -11.7%, while earnings growth is N/A due to the company's current unprofitable status. The negative revenue growth indicates a contraction in sales, which is a primary concern as it prevents any potential for earnings acceleration. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings or cash flow to fund operations and R&D rather than distributing income to shareholders. This non-dividend status implies that the company reinvests any available capital back into the business to attempt to reverse the negative growth trends and restore profitability. Consequently, the overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, forcing reliance on capital markets or cash reserves to sustain operations until positive growth can be re-established.